Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BNT162

            Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Fosun Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement December 16, 2020

            Details:

            BioNTech and Shanghai Fosun Pharmaceutical today announced an agreement to supply Mainland China with 100 million doses initially of their BNT162 mRNA-based vaccine candidate against COVID-19 in 2021, subject to regulatory approval.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bulevirtide Acetate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Hepcludex

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: $1,762.0 million Upfront Cash: $1,400.0 million

            Deal Type: Acquisition December 10, 2020

            Details:

            The acquisition will provide Gilead with Hepcludex™ (bulevirtide), which was conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020.